TNF スーパーファミリー、または腫瘍壊死因子スーパーファミリーは、そのメンバーが癌において示す二重の役割について、最近多くの注目を集めています。TNF はがんのプロモーターとリプレッサーの両方の機能を有するため、近年、TNF ファミリーがその治療上の有望性について検討されています。同様に、これらのタンパク質の受容体も治療の可能性について調査されており、TNFファミリーのメンバーと相互作用するのを防ぐことで対処されています。腫瘍壊死因子受容体の 1 つである CD137 は、いくつかの適応症にまたがる可能性があるため、最近、がん治療領域において関心を集めています。現在、多くの製薬会社が、さまざまながんの治療に使用できる CD137 に結合する抗体の開発に取り組んでいます。
目次
1. Brief Introduction To CD137
1.1 Clinical Overview
1.2 Biological History Of CD137
1.3 CD137 Hosting An Era Of Agonists Over Antagonists
1.4 Bi-Directional Signaling In CD137
2. CD137 Progression In Autoimmune and Infectious Diseases
2.1 Autoimmune Disorders
2.2 Viral Infections
2.3 Bacterial infections
3. CD137 Antibodies By Cancer and Ongoing Clinical Trials
3.1 Leukemia
3.2 Lymphoma
3.3 Non-Small Cell Lung Cancer
3.4 Melanoma
3.5 Breast Cancer
3.6 Colorectal Cancer
4. Global CD137 Antibodies Clinical Trials Overview
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Phase
4.5 By Patient Segment
5. Global CD137 Antibodies Clinical Trials Insight By Company, Indication and Phase
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II
6. CD137 Targeting Proprietary Technology Platforms By Companies
7. CD137 Antibodies Market and Clinical Trends Outlook
7.1 Current Market Trends
7.2 Clinical Stance
7.3 Drug Designations
7.4 Future Market Opportunity Outlook
8. CD137 Therapeutic Approaches By Antibodies Classification
8.1 Monoclonal Antibody Based Strategies
8.2 Bispecific Antibody Centered Approaches
8.3 Trispecific Antibody Established Strategies
8.4 Tetraspecific Antibody Strategies
9. Monotherapy and Combination Therapy With CD137 Antibodies
10. Competitive Landscape
10.1 ABL Bio
10.2 Adagene
10.3 Alligator Bioscience
10.4 BeiGene
10.5 Bicycle Therapeutics
10.6 BioNTech
10.7 Biotheus
10.8 Crescendo Biologics
10.9 Cue Biopharma
10.10 Eutilex
10.11 F-star Therapeutics
10.12 Genmab
10.13 I-MAB Biopharma
10.14 Lyvgen Biopharma
10.15 Molecular Partners
10.16 OriCell Therapeutics
10.17 Pieris Pharmaceuticals
10.18 Shanghai Henlius Biotech
10.19 Sichuan Baili Pharmaceutical
10.20 SystImmune
List of Figures & Tables
Figure 1-1: Immune Regulation Mechanisms Of Anti-CD137 Monoclonal Antibody
Figure 1-2: Schematic Depiction Of Bidirectional Signaling By CD137-CD137L
Figure 3-1: Dual Co-Stimulatory Trial - Study Initiation and Expected Completion Year
Figure 3-2: RO7227166 - Study Initiation and Expected Completion Year
Figure 3-3: YH004 - Study Initiation and Expected Completion Year
Figure 3-4: GNC-038 - Study Initiation and Expected Completion Year
Figure 3-5: UCD19 CAR T - Study Initiation and Expected Completion Year
Figure 3-6: EU101 - Study Initiation and Expected Completion Year
Figure 3-7: GEN106 - Study initiation and Expected Completion Year
Figure 3-8: HLX35 - Study Initiation and Expected Completion Year
Figure 3-9: Nivolumab and ADG106 - Study Initiation and Expected Completion Year
Figure 3-10: INBRX-105 - Study Initiation and Expected Completion Year
Figure 3-11: NM21-1480 - Study Initiation and Expected Completion Year
Figure 3-12: JAVELIN Medley - Study Initiation and Completion Year
Figure 3-13: AGEN2373 - Study Initiation and Completion Year
Figure 3-14: AVIATOR Study - Study Initiation and Expected Completion Year
Figure 3-15: YH32367 - Study Initiation and Expected Completion Year
Figure 3-16: NM21-140 - Study Initiation and Estimated Completion Year
Figure 3-17: RO7122290 - Study Initiation and Expected Completion Year
Figure 3-18: EU101 - Study Initiation and Completion Year
Figure 4-1: Global - CD137 Targeting Antibodies Clinical Pipeline by Company (Numbers), 2023
Figure 4-2: Global - CD137 Targeting Antibodies Clinical Pipeline by Country (Numbers), 2023
Figure 4-3: Global - CD137 Targeting Antibodies Clinical Pipeline by Indication (Numbers), 2023
Figure 4-4: Global - CD137 Targeting Antibodies Clinical Pipeline by Phase (Numbers), 2023
Figure 4-5: Global - CD137 Targeting Antibodies Clinical Pipeline by Patient Segment (Numbers), 2023
Figure 6-1: ACG106 - Anti-CD137 NEObody
Figure 6-2: ADG206 - Anti-CD137 POWERbody
Figure 6-3: DUObody - Production Process
Figure 6-4: The MATCH Format
Figure 6-5: General Format Of GNC-039
Figure 6-6: General Format Of GNC-035
Figure 6-7: General Format Of GNC-038
Figure 8-1: ATOR-1017 - Mechanism Of Action
Figure 8-2: EU101 - Mode Of Action
Figure 8-3: LVGN6051 - Mechanism Of Action
Figure 8-4: ABL503 - Structure and Mechanism Of Action
Figure 8-5: FS120 - Improving PD-1 and hemotherapy Responses
Figure 8-6: MP0310 - Mechanism Of Action
Table 7-1: Global - Future Regional Powers for CD137 Therapy Market
Table 8-1: Bispecific Antibody Approaches Targeting CD137/4-1BB
Table 8-2: Trispecific Antibody Formats Targeting CD137
Table 8-3: Tetraspecific Antibody Formats For Targeting CD137/4-1BB
Table 9-1: CD137 Targeting Monotherapy Regimes Under Clinical Trials
Table 9-2: Combinational Strategies With CD137 Therapies
